Last reviewed · How we verify
DIBENZEPIN
Dibenzipine is a marketed drug that operates by blocking the histamine H1 receptor, currently positioned in a competitive landscape dominated by off-patent tricyclic antidepressants such as desipramine, imipramine, clomipramine, trimipramine, and amitriptyline, all of which have multiple generic versions available. A key strength of Dibenzipine is its unique mechanism of action through the histamine H1 receptor, distinguishing it from its competitors which primarily target serotonin and norepinephrine reuptake. The primary risk facing Dibenzipine is the expiration of its key composition patent in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | DIBENZEPIN |
|---|---|
| Drug class | dibenzepin |
| Target | 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |